|
The Immunohistochemistry Antibody Company
|
- Home
-
Products
- All Antibodies
- IHC-plus Antibodies
-
Services
- Immunohistochemistry Studies
- Tissue Cross-Reactivity Screening
- Distributors
-
Resources
- About our Tissue Bank
- Customer Support
- How to Buy
- IHC-plus Protocol
- LSBio Media
- Publications
- Antibody Reports
-
Company
- About LifeSpan
- Press Releases
- Holiday Schedule
- Contact Us
|
|
Liver Cancer Screen 22 Tissue Microarray - LS-SLVCA22
This tissue microarray is available for use in LSBio Immunohistochemistry Studies only.
|
|
| Catalog ID: |
LS-SLVCA22 |
| Product Name: |
Liver Cancer Screen 22 |
| Description: |
Liver cancer with stage/grade |
| Format: |
FFPE |
| Category: |
Human Tumor |
| QA/QC: |
H&E reviewed |
| Storage: |
Short term RT; Long term 4ºC |
| Clinical History: |
No |
| Tissue Marker: |
No |
| Stage/Grade: |
Yes |
| Cases: |
48 |
| Cores: |
48 |
| Slides Per Set: |
1 |
LS-SLVCA22 Tissue Microarray Map
Slide Number 1
| LABEL | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | | A | Liv | Liv | Liv | Liv | Liv | Liv | Liv | Liv | | B | Liv | Liv | Liv | Liv | Liv | Liv | Liv | Liv | | C | Liv | Liv | Liv | Liv | Liv | Liv | Liv | Liv | | D | Liv | Liv | Liv | Liv | Liv | Liv | Liv | Liv | | E | Liv | Liv | Liv | Liv | Liv | Liv | Liv | Liv | | F | Liv | Liv | Liv | Liv | Liv | Liv | Liv | Liv |
|
Diagnosis Type Legend| Benign non-neoplastic | Diseased | Inflammatory | Malignant | Metastatic | Tumor | Unknown |
Element Tissue LegendLiver (Liv);
LS-SLVCA22 Element Details
| Slide | Position | Species | Gender | Age | Tissue | Diagnosis | Diagnosis Type | TNM Tumor Classification | Tumor Grade | Tumor Stage |
|---|
| 1 | A1 | Human | M | 59 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 1 | III |
| 1 | A2 | Human | M | 56 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 1 | III |
| 1 | A3 | Human | M | 64 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | A4 | Human | M | 57 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | A5 | Human | M | 38 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | A6 | Human | F | 40 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T4N0M0 | 3 | I |
| 1 | A7 | Human | M | 51 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | A8 | Human | M | 58 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | B1 | Human | M | 49 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | B2 | Human | M | 35 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | B3 | Human | F | 36 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | B4 | Human | M | 68 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | B5 | Human | M | 65 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | B6 | Human | F | 35 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | B7 | Human | M | 39 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | B8 | Human | M | 65 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | C1 | Human | M | 58 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | C2 | Human | M | 46 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | C3 | Human | F | 62 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | C4 | Human | M | 37 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | C5 | Human | M | 39 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | C6 | Human | M | 75 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | C7 | Human | M | 48 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | C8 | Human | M | 44 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | D1 | Human | M | 45 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | D2 | Human | M | 68 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | D3 | Human | F | 52 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | D4 | Human | M | 48 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | D5 | Human | M | 49 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | D6 | Human | M | 59 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | D7 | Human | M | 43 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | D8 | Human | M | 38 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 3 | III |
| 1 | E1 | Human | M | 56 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 3 | III |
| 1 | E2 | Human | M | 58 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T3N0M0 | 3 | III |
| 1 | E3 | Human | M | 61 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | E4 | Human | M | 56 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | E5 | Human | M | 55 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | E6 | Human | M | 59 y | Liver (Liv) | Hepatocellular carcinoma with necrosis | Malignant | T2N0M0 | 3 | II |
| 1 | E7 | Human | M | 32 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | 3 | II |
| 1 | E8 | Human | M | 62 y | Liver (Liv) | Hepatocellular carcinoma with necrosis | Malignant | T2N0M0 | | II |
| 1 | F1 | Human | M | 60 y | Liver (Liv) | Cholangiocarcinoma | Malignant | T3N0M0 | 1 | III |
| 1 | F2 | Human | F | 60 y | Liver (Liv) | Cholangiocellular carcinoma with necrosis | Malignant | T2N0M0 | 2 | II |
| 1 | F3 | Human | F | 57 y | Liver (Liv) | Cholangiocarcinoma | Malignant | T2N0M0 | 2 | II |
| 1 | F4 | Human | M | 55 y | Liver (Liv) | Cholangiocarcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | F5 | Human | M | 45 y | Liver (Liv) | Cholangiocellular carcinoma with necrosis | Malignant | T2N0M0 | 2 | II |
| 1 | F6 | Human | M | 40 y | Liver (Liv) | Cholangiocarcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | F7 | Human | F | 55 y | Liver (Liv) | Cholangiocarcinoma | Malignant | T3N0M0 | 2 | III |
| 1 | F8 | Human | M | 51 y | Liver (Liv) | Cholangiocarcinoma | Malignant | T3N0M0 | 2-3 | III |
Copyright © 2013 LifeSpan BioSciences, Inc. All Rights Reserved
